Abstract Gestational diabetes mellitus (GDM) associates with increased L-arginine transport and extracellular concentration of adenosine in human umbilical vein endothelial cells (HUVECs). In this study we aim to determine whether insulin reverses GDM-increased L-arginine transport requiring adenosine receptors expression in HUVECs. Primary cultured HUVECs from full-term normal (n = 38) and diet-treated GDM (n = 38) pregnancies were used. Insulin effect was assayed on human cationic amino acid transporter 1 (hCAT1) expression (protein, mRNA, SLC7A1 promoter activity) and activity (initial rates of L-arginine transport) in the absence or presence of adenosine receptors agonists or antagonists. A 1 adenosine receptors (A 1 AR) and A 2A AR expression (Western blot, quantitative PCR) was determined. Experiments were done in cells expressing or siRNA-suppressed expression of A 1 AR or A 2A AR. HUVECs from GDM exhibit higher maximal transport capacity (maximal velocity (V max )/ apparent Michaelis Menten constant (K m ), V max /K m ), which is blocked by insulin by reducing the V max to values in cells from normal pregnancies. Insulin also reversed the GDMassociated increase in hCAT-1 protein abundance and mRNA expression, and SLC7A1 promoter activity for the fragment −606 bp from the transcription start point. Insulin effects required A 1 AR, but not A 2A AR expression and activity in this cell type. In the absence of insulin, GDM-increased hCAT-1 expression and activity required A 2A AR expression and activity. HUVECs from GDM pregnancies exhibit a differential requirement of A 1 AR or A 2A AR depending on the level of insulin, a phenomenon that represent a condition where adenosine or analogues of this nucleoside could be acting as helpers of insulin biological effects in GDM.
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Introduction
Gestational diabetes mellitus (GDM) characterizes by abnormal maternal D-glucose metabolism and altered insulin signaling in the fetoplacental circulation [1] [2] [3] . GDM also associates with increased uptake of the cationic amino acid L-arginine [4] , the substrate for nitric oxide (NO) synthesis by the endothelial NO synthase (eNOS) [5] , in human umbilical vein endothelial cells (HUVECs), changes referred as GDM-associated fetoplacental endothelial dysfunction [3, 6] . The latter is reinforced with findings showing that uptake of the endogenous nucleoside adenosine, a potent vasodilator in the human fetoplacental vasculature [7, 8] and other vascular beds [9] [10] [11] , is also reduced in HUVECs from GDM pregnancies [8, 12] . Reduced adenosine transport leads to increased extracellular levels of adenosine in HUVECs primary cultures from GDM pregnancies, a finding that agrees with the elevated adenosine plasma level detected in human umbilical vein blood from GDM pregnancies [8, 13] . We reported that activation of A 2A adenosine receptors (A 2A AR) is required for the increase caused by insulin on L-arginine transport via the human cationic amino acid transporter 1 (hCAT-1), a Na + -and pH-independent membrane transporter (apparent K m 100 μM) [14, 15] , and eNOS activity in HUVECs from normal pregnancies [6, 12] . Additionally, insulin restores GDM-reduced adenosine transport [15] in this cell type. However, whether insulin effect requires activation of adenosine receptors (ARs) in the fetoplacental endothelium from GDM pregnancies is unknown [3, 11] . We hypothesize that insulin will reverse the GDM-associated increase in hCAT-1 expression and activity requiring expression and activation of ARs in HUVECs. Our results show that increased L-arginine transport in HUVECs from GDM pregnancies is reversed by insulin to values in cells from normal pregnancies via a mechanism where A 1 AR play a role.
Materials and methods
Human umbilical cords and study groups Umbilical cords were collected after delivery from 38 full-term normal or 38 full-term GDM pregnancies. Ethnicity of patients included in this study was Hispanic. The investigation conforms to the principles outlined in the Declaration of Helsinki. Ethics Committee approval from the Faculty of Medicine of the Pontificia Universidad Católica de Chile and informed consent of patients (all of them from the Hospital Clínico UC in Santiago de Chile) were obtained. Patients between the 24-28 weeks of gestation with basal glycemia >5 mM (>90 mg/dL, i.e., overnight starvation) and with >7.9 mM (>140 mg/dL) at 2 h after an oral glucose load (75 g) were diagnosed as gestational diabetes (according with the Perinatal Guide 2014 report from the Health Ministry of Chile) and subjected to dietary treatment with 1500 kcal/day and a maximum of 200 g per day carbohydrates ( Table 1 ). The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated from:
where Insulin is in micro unit per millilitre and Glucose is basal glycemia in millimole per litre [16, 17] . Insulin sensitivity (IS) was derived from these values by IS ¼ 1 IR ⋅100 (expressed in %). Additionally, β cell function (β, expressed in %) was estimated from:
Cell culture
Confluent HUVECs primary cultures (37°C, 5 % CO 2 ) were cultured in medium 199 (M199; Gibco Life Technologies, Carlsbad, CA, USA) up to passage 3 as described [6] . The culture medium was supplemented with 0.04 nM (~5.1 μU/mL) or 0.07 nM (~7.9 μU/mL) insulin for normal or GDM pregnancies, respectively [8] . Experiments were performed in the absence (referred as 'without insulin' or 'in the absence of insulin') or presence (referred as 'with insulin' or 'in the presence of insulin') of exogenous 1 nM insulin for 8 h. Cells were also exposed to 30 nM (2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol (CPA, A 1 AR agonist) (Sigma, Atlanta, GA, USA), 3 AR agonist) (Tocris Bioscience), and 30 nM 3-propyl-6-ethy l -5 [ ( e t h y l t h i o ) c a r b o n y l ] -2 -p h e n y l -4 -p r o p y l -3 -pyridinecarboxylate (MRS-1523, A 3 AR antagonist) (Tocris Bioscience) [6] .
L-Arginine transport
Overall 0-1000 μM L-arginine transport (3 μCi/mL L-[ 3 H]arginine (NEN, Dreieich, FRG), 1 min incubation, 37°C) was measured as described [6] . Briefly, transport assays were performed in Krebs ((mM): NaCl 131, KCl 5.6, NaHCO 3 25, NaH 2 PO 4 1, Hepes 20, CaCl 2 2.5, MgCl 2 1 (pH 7.4, 37°C)) in cells preincubated (12-14 h ) in phosphate-buffered saline (PBS) solution ((mM): 130 NaCl, 2.7 KCl, 0.8 Na 2 HPO 4 , 1.4 KH 2 PO 4 (pH 7.4, 4°C)) containing 0.25 % newborn and 0.25 % fetal calf sera. PBS and Krebs solutions were also supplemented with 2 U/mL adenosine deaminase 1. ATP, ADP, AMP, or adenosine was not detected in PBS or Krebs solutions as assayed by high-performance light chromatography (not shown) as described [12] . Cell monolayers were rinsed with ice-cold Krebs to terminate tracer uptake. Radioactivity in formic acid cell digests was determined by liquid scintillation counting, and uptake was [6] .
Initial rate for transport (i.e., linear uptake up to 1 min) was derived from slope of linear phase of 100 μM L-arginine transport. Values for L-arginine transport were adjusted to the one phase exponential association equation considering the least squares fit:
where v i is initial velocity, V m is mayor velocity at a given time (t) and L-arginine concentration, and e and k are constants. Overall L-arginine transport at initial rates was adjusted to the Michaelis-Menten hyperbola plus a nonsaturable, linear component as described [6] . Saturable L-arginine transport kinetic parameters maximal velocity (V max ) and apparent MichaelisMenten constant (K m ) of transport were calculated as described [6] . The relative contribution of GDM, insulin, or ARs to the saturable L-arginine transport kinetic parameters was estimated from the maximal transport capacity (V max /K m ) values for L-arginine transport by:
where C V max and C K m are the kinetics parameters for Larginine transport in control conditions in cells from normal or GDM pregnancies, and X V max and X K m are kinetics parameters of L-arginine transport in HUVECs from normal or GDM pregnancies exposed to different experimental conditions [6, 8] .
Trans-stimulation experiments for saturable L-arginine transport (100, 250, 500 μM) were performed in cells incubated (2 h) with Krebs solution containing 10 mM L-lysine. Incubation medium was removed and replaced by L-lysinefree Krebs and transport was determined as above [18] .
Reverse transcription and quantitative RT-PCR
Experiments were performed using a Step One real time PCR system (Applied Biosystem, CA, USA) in a reaction mix containing 0.2 μM primers and master mix provided in the brilliant SYBR green qPCR Master Mix (Applied Biosystem, CA, USA) as described [6] . Hot Start Taq DNA polymerase was activated (15 min, 95°C), and assays included a 95°C denaturation (15 s), annealing (20 s) at 54°C (hCAT-1 and 28S), and extension at 72°C (hCAT-1 and 28S, 10 s). Fluorescent product was detected after 3-s step to 5°C below the product melting temperature (T m ). Product specificity was confirmed by agarose gel electrophoresis (2 % w/v) and melting curve analysis. The product T m values were 79.1°C for hCAT-1 and 86.7°C for 28S. hCAT-1 and 28S standards were prepared as described [6] . Oligonucleotide primers are as follows: hCAT-1 (sense) 5′-GAGTTAGATCCAGCAGACCA-3′, hCAT-1 (anti-sense) 5′-TGTTCACAATTAGCCCAGAG-3′, 28S (sense) 5′-TTGAAAATCCGGGGGAGAG-3′, 28S (antisense) 5′-ACATTGTTCCAACATGCCAG-3′. Expected size products for hCAT-1 (151 bp) and 28S (105 bp) were confirmed in PCR experiments. The 28S rRNA number of copies was unaltered (P > 0.05, n = 16) in all experimental conditions (not shown).
Western blotting
Proteins (70 μg) separated by polyacrylamide gel (10 %) electrophoresis were probed with a primary polyclonal goat antihCAT-1 (1:500), goat anti-A 1 AR (1:1000), mouse anti-A 2A AR (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-A 2B AR (1:1000) or anti-A 3 AR (1:1000) (Abcam, Cambridge, UK), or monoclonal mouse anti-β-actin (1:3000) (Sigma Aldrich, St Louis, MO, USA) antibodies [6] . Proteins were detected by enhanced chemiluminescence in a ChemiDoc-It® 510 Imagen System (UVP, LCC Upland, CA, USA) and quantified by densitometry.
HCAT-1 promoter cloning
Genomic DNA was isolated using the Wizard SV Genomic DNA Purification System (Promega, Madison, WI, USA). The sequences −1606 and −650 bp from the transcription start point of the SLC7A1 gene (GenBank: AL596114) were PCRamplified using Elongase Enzyme System (Invitrogen) and cloned into pGL3-basic reporter system [6, 18] . The pGL3-hCAT-1 reporter constructs generated were pGL3-hCAT-1 −1606 and pGL3-hCAT-1
.
Transient transfection
Sub-confluent (60-80 %) HUVECs primary cultures were resuspended in serum-free M199. Aliquots of cell suspension (0.5 mL, 3.2 × 10 6 cells/mL) were mixed with 10 μg of pGL3-hCAT1 −1606 or pGL3-hCAT1 −650 constructs, pGL3-Basic (empty pGL3 vector), pGL3-Control (Simian Virus 40 promoter (SV40) pGL3 vector), and the internal transfection control vector pRL-TK expressing Renilla luciferase (Promega) [6] . After electroporation (300 V, 700 μF, 5-10 ms) (Gene Pulser II System, BioRad, CA, USA), cells were cultured (48 h) in M199 containing 2 % FCS. Transfection efficiency was estimated by transfection of the pEGFP-N3 vector (Clontech, Mountain View, CA, USA) and fluorescent cells were counted under an inverted fluorescent microscope (Leica DMIL; Wetzlar, Germany).
Luciferase assay
Firefly and Renilla luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) in a Sirius luminometer (Berthold Detection System; Oak Ridge, TN, USA) [6] .
Adenosine receptors suppression
Since the pharmacological approach used in this study suggested that A 2B AR and A 3 AR may not be involved in the effect of insulin, we focused in generating cells knockdown for A 1 AR and A 2A AR. Suppression of A 1 AR and A 2A AR 
Normal pregnancies 
Statistical analysis
Values are mean ± SD (range) or SEM, with n = 38 different cell cultures (3-4 replicates) from normal or GDM pregnancies. The normality of the data was determined with Kolmogorov-Smirnov test. Comparisons between two and more groups were performed by means of Student's unpaired t test and analysis of variance (ANOVA), respectively. If the ANOVA demonstrated a significant interaction between variables, post hoc analyses were performed by the multiplecomparison Bonferroni correction test. P < 0.05 was considered statistically significant. The statistical software GraphPad Instat 3.0b and Graphpad Prism 7.0a.65 (GraphPad Software Inc., San Diego, CA, USA) were used for data analysis. P < 0.05 was considered statistically significant.
Results

Patients and newborns
Normal or GDM pregnancies were singleton and pregnant women were normotensive, nonsmoking, non-alcohol or drug consuming, and without intrauterine infection or any other medical or obstetrical complications (Table 1) . Newborns to GDM pregnancies were heavier at birth, with higher umbilical vein insulin and HOMA-IR, but lower HOMA-IS compared with normal pregnancies.
L-Arginine transport
In the absence of insulin, overall transport of L-arginine was unaltered by ARs agonists or antagonists in cells from normal pregnancies (Fig. 1a) . Insulin increased overall transport in this cell type, an effect blocked by an A 2A AR antagonist. In the absence of insulin, overall L-arginine transport was higher in cells from GDM compared with normal pregnancies. GDM effect was reversed by an A 2A AR antagonist to values in cells from normal pregnancies. Insulin reversed GDM-increase in transport to values in normal pregnancies, an effect blocked by an A 1 AR antagonist. Overall L-arginine transport kinetics was semisaturable (not shown), and non-saturable transport component (i.e., K D ) was similar in normal or GDM pregnancies (Table 2) and unaltered by insulin or agonists or antagonists for ARs. However, insulin increased the v i of transport in normal pregnancies, an effect blocked by the A 2A AR antagonist. In the absence of insulin, GDM-increase in v i was blocked by the A 2A AR antagonist. Insulin reversed GDM effect on v i , an effect blocked by the A 1 AR antagonist (Table 2) .
After subtracting the K D from overall transport, the resulting saturable transport of L-arginine (Fig. 1b) coursed with higher V max and V max /K m values, without variations in the apparent K m in cells from normal pregnancies exposed to insulin ( Table 2) . Similar results were found in cells from GDM pregnancies in the absence of insulin. However, insulin reversed GDM-increase in V max and V max /K m to values in normal pregnancies. The A 2A AR antagonist blocked insulin effect in normal pregnancies. In addition, this antagonist blocked GDM effect on saturable transport in the absence of insulin. However, the A 1 AR antagonist blocked insulin effect on saturable transport in GDM pregnancies. Parallel experiments show that saturable transport of 100, but not 250 or 500 μM L-arginine, was trans-stimulated by L-lysine reaching similar values in both conditions (Fig. 1c) .
HCAT-1 expression
Insulin increased hCAT-1 protein abundance in HUVECs from normal pregnancies to values in GDM (Fig. 2a) , but reversed GDM-increase in hCAT-1 to values in normal pregnancies in absence of this hormone. Insulin effect in normal pregnancies was unaltered by the A 1 AR antagonist, but this antagonist blocked this hormone's effect in GDM. However, the A 1 AR antagonist in the absence of insulin did not alter the GDM-increased hCAT-1 protein abundance. Insulin effect in cells from GDM was unaltered by an A 2A AR antagonist; however, this antagonist alone blocked the GDM-increase in hCAT-1 (Fig. 2b) . Insulin increased hCAT-1 protein abundance in normal pregnancies was blocked by A 2A AR antagonist, but this antagonist did not alter hCAT-1 protein abundance in the absence of insulin. Similar responses to insulin were obtained for hCAT-1 mRNA expression in both cell types (Fig. 2c, d ).
SLC7A1 promoter activity
Reporter luciferase activity in cells from normal pregnancies transfected with pGL3-hCAT-1 −1606 or pGL3-hCAT-1
constructs was lower compared with GDM in the absence of insulin (Fig. 2e) . Insulin increased the reporter activity for both constructs in normal pregnancies. , but not with the pGL3-hCAT-1 −650 construct. In the absence of insulin, GDM-increased reporter activity for both constructs was reversed only by the A 2A AR antagonist. However, insulin reversed the GDM increase in the reporter activity for both constructs, an effect that was abolished by the A 1 AR antagonist and unaltered by the A 2A AR antagonist.
Adenosine receptors expression
A 1 AR protein abundance was higher in cells from GDM compared with normal pregnancies and was unaltered by insulin in both cell types (Fig. 3a) . On the contrary, A 2A AR was lower in cells from GDM compared with normal pregnancies, and insulin increased this ARs protein abundance in both cell types. However, A 2B AR or A 3 AR protein abundance was unaltered by insulin in cells from normal or GDM pregnancies. (Fig. 4b) cells. In addition, insulin effect in hCAT-1 mRNA (Fig. 4c) was similar to hCAT-1 protein abundance and activity in both cell types.
Adenosine receptors suppression and L-arginine transport
Insulin increase in pGL3-hCAT-1 −1606 construct reporter activity was abolished in KD A 2A AR, but unaltered in KD A 1 AR cells from normal pregnancies (Fig. 4d) 
Discussion
This study shows that GDM-associated increase in L-arginine transport is mediated by hCAT-1 in HUVECs and is reversed by insulin to values in cells from normal pregnancies via a mechanism requiring expression and activity of A 1 AR. This effect of insulin includes reestablishment of hCAT-1 maximal transport capacity (V max /K m ), and protein abundance and mRNA expression. Insulin restored SLC7A1 (for hCAT-1) gene expression, likely due to activation of a promoter region located between −650 bp from the transcription start point of this gene. In the absence of insulin, GDM-increased hCAT-1 expression and activity depends on A 2A AR expression. Thus, GDM effect on hCAT-1 expression and activity results from 
L-Arginine transport in GDM
L-Arginine transport is mediated by more than one transport system in HUVECs, from where the very-high affinity system y + L (K m~1 μM), and the system y + family members hCAT-1 (K m~1 00 μM) and hCAT-2B (K m~2 50 μM) [6, 14, 15, 18] play crucial roles. In HUVECs from GDM, the overall Larginine transport was semisaturable with a non-saturable Larginine transport component (K D ) detected from L-arginine concentrations >250 μM, suggesting that L-arginine transport was likely mediated by at least two membrane transport mechanisms in this cell type. The possibility that hCAT-1 mediates L-arginine transport is likely since the apparent K m value for saturable transport is within the range of this transport system in HUVECs [6, 18] and other cell types [14, 15, 19, 20] . In addition, L-arginine transport was trans-stimulated by~7-fold only when a concentration of L-arginine (100 μM in this study) was close to the K m for hCAT-1. Since trans- In the presence of an extracellular level of insulin similar to that detected in the human umbilical vein blood in gestational diabetes mellitus (GDM) (0.07 nM insulin (see Table 1 )), the human cationic amino acid transporter 1 (hCAT-1) protein abundance and availability at the plasma membrane of human umbilical vein endothelial cells (HUVECs) result in an increase ( ) in transport of L-arginine (orange arrow) compared with cells from normal pregnancies. This phenomenon is maintained by a higher expression of the SLC7A1 gene for hCAT-1 leading to higher hCAT-1 mRNA expression and protein abundance. stimulation of hCAT-1-mediated L-arginine transport by Llysine is known to be higher (~5-10 fold) than hCAT-2B-mediated transport (~2-3 fold) [14, 15, [19] [20] [21] , involvement of hCAT-2B transport activity in HUVECs from GDM pregnancies is unlikely.
The increased V max /K m for saturable transport in cells from GDM was paralleled by similar changes in hCAT-1 protein abundance. Thus, increased transport could result from higher bioavailability of this type of membrane transporters in HUVECs from GDM pregnancies. This phenomenon could be due to higher SLC7A1 expression since the promoter activity for the region from −1606 bp to the transcription start point for this gene and the hCAT-1 mRNA expression were increased in a similar proportion (~2.6-fold) to the increase detected for V max /K m and hCAT-1 protein abundance in cells from GDM pregnancies.
Adenosine receptors involvement on insulin effect
We previously reported that insulin increased the V max /K m for L-arginine transport and hCAT-1 expression in HUVECs from normal pregnancies [6] . In the present study, insulin reverses the GDM-associated increase in V max /K m and hCAT-1 expression in HUVECs. This apparent contradictory effect of insulin on L-arginine transport agrees with previous reports showing a similar dual effect of this hormone on membrane transport mechanisms, including the human equilibrative nucleoside transporters 1 (hENT1) and hENT2 for adenosine uptake in HUVECs [8, 12] and human placental microvascular endothelial cells (hPMECs) [22] from normal or GDM pregnancies. Thus, a dual effect of insulin is not restricted to Larginine transport via hCATs. Interestingly, insulin did not alter the K D in cells from normal or GDM pregnancies, suggesting that a parallel plasma membrane transport mechanism to hCAT-1 is either unaltered or minimally altered reaching a negligible influence on overall transport by this hormone. The latter is supported by previous findings showing that insulin did not alter the protein abundance of hCAT-2A/B (i.e., low affinity, high capacity hCAT-2A and high affinity, low capacity hCAT-2B) in HUVECs from normal pregnancies [6] . Additionally, it is reported that insulin increases CAT-1, but not CAT-2B mRNA level and CAT-1-mediated L-arginine transport in rat neonatal ventricular myocites [23] . Thus, a selective phenomenon regarding modulation of hCAT1 and hCAT-2B by insulin is likely in human placenta endothelium.
Protein abundance for A 1 AR is higher, but A 2A AR is lower in cells from GDM compared with normal pregnancies in the absence of insulin, suggesting that these two ARs subtypes play a role in HUVECs under this pathological condition. Since GDM-increased V max /K m for transport was blocked by an A 2A AR antagonist in the absence of insulin, this ARs subtype could be acting as hCAT-1 activator. Extracellular level of adenosine in primary cultures of HUVECs [4, 24] , hPMECs [22] , and in the umbilical vein blood [6, 8, 22, 25] from GDM pregnancies is higher (~1 μM) than in normal pregnancies (~0.4 μM). Since A 2A AR affinity for adenosine (~0.3 μM) [10, 26] is within this range of the adenosine concentration detected in GDM, an activated state of these receptors is expected. However, we cannot rule out the possibility that the increase in the extracellular concentration of adenosine could lead to adenosine-reduced expression of A 2A AR in HUVECs from GDM. Additionally, as a potential limitation of our study, it is feasible that adenosine release from HUVECs after 1 min of incubation (time used for transport assay measurements), even in the presence of adenosine deaminase 1, was enough to saturate A 1 AR and A 2A R and cause a basal increase in L-arginine transport in this cell type. Since HUVECs from GDM pregnancies are shown to express hENT1 and hENT2 accounting for equilibrative adenosine transport [8, 12] , and because hENT1 expression and activity is downregulated in HUVECs from GDM [8, 12] , we speculate on the possibility that a potential efflux of adenosine via hENT2 from HUVECs is likely. Even when the affinity of A 1 AR and A 3 AR for adenosine are~0.1 and~0.3 μM, respectively [10] , agonists or antagonists for these ARs subtypes did not alter GDM-effect on transport, suggesting that their involvement in this phenomenon is unlikely.
Insulin reverses GDM-associated increase in L-arginine transport most likely via a mechanism that requires A 1 AR since an antagonist for A 1 A 2A AR cells. Insulin effect on L-arginine transport in GDM depends on an A 1 AR-dependent activation of SLC7A1 expression at the promoter region −650 bp from the transcription start point. Previous studies show that this region of the SLC7A1 promoter contains at least four consensus sites between −177 and −105 bp from the transcription start point for the general transcription factor specific protein 1 (Sp1), and that Sp1 binding to these sites is increased by insulin in cells from normal pregnancies [18] . Thus, Sp1 as well as other transcription factors associated with the control of expression of membrane transporters families, such as C/EBP homologous protein 10 (CHOP) binding to SLC7A1 in C6 rat glioma cells [27] , could be responsible of insulin modulation of hCAT-1 expression in cells from GDM pregnancies. There is no information addressing a role for Sp1 as a cell signaling mechanism triggered by activation of ARs [10, 11, 26] . Thus, we do not rule out the possibility that biological effects of insulin could require adenosine acting via A 1 AR as a helper or positive regulator via Sp1 activation in HUVECs from GDM pregnancies. Since umbilical blood insulin level in GDM pregnancies is higher (~1.9-fold) compared with normal pregnancies, and because a larger concentration of insulin was required to reverse GDM increase in L-arginine transport in vitro, the observed increase in the plasma insulin at the fetal circulation may be not enough to restore GDM-associated alterations in the human fetoplacental circulation. The latter could also result from fetal insulin resistance as suggested by an elevated HOMA-IR value (~2.2-fold versus normal pregnancies) detected in this group of newborns, agreeing with previous reports in GDM [8, 22, 28] .
In summary, GDM is associated with increased L-arginine transport in HUVECs, which results from higher hCAT-1 expression and activity. Insulin reverses GDM-associated effects on transport requiring activation and higher expression of A 1 AR in this cell type. In the absence of insulin, GDM effect on hCAT-1 expression and activity is dependent on A 2A AR expression and activation (see Fig. 5 ). A simple interpretation of our results is that insulin increases adenosine extracellular concentration in cells from normal pregnancies leading to predominant activation of A 2A AR to mediate insulin increase in L-arginine transport. However, cells from GDM pregnancy show induction of A 1 AR with a predominant response resulting from activation of this type of receptor to mediate insulin decrease in L-arginine transport. Thus, a differential modulatory effect of insulin is played by adenosine receptors in endothelial cells from the macrovasculature in the human placenta from GDM. Since this GDM-associated fetal hyperinsulinemia is a condition that seems not to be enough to restore umbilical vein endothelial function, and because a state of less sensitivity to insulin in GDM fetoplacental vasculature is feasible, a higher concentration of insulin could be required to actually see a beneficial effect of this hormone. Insulin therapy is a protocol applied in pregnant women with GDM that are not responsive to diet and/or exercise to normalize their glycemia. However, this approach associates with a risk of the offspring to develop adulthood diseases such as diabetes mellitus type 2 [29, 30] and of the mother to course with GDM in a future pregnancy [31] . Thus, we emphasize the need of a therapeutical approach considering the potential metabolic modulation of circulating adenosine level and/or adenosine receptors activation/inactivation complementing insulin therapy protocol in pregnant women with GDM to restore fetoplacental endothelial dysfunction for the benefit of the mother and the newborn [3] .
